Objective: To report long-term results of a phase I/II study conducted in a single center in order to investigate the effect of hemopoietic stem cell transplantation (HSCT) in the treatment of multiple sclerosis (MS).
In 1995, we launched an unblinded trial to study the effect of intense immunosuppressive chemotherapy and hemopoietic stem cell transplantation (HSCT) in the treatment of aggressive multiple sclerosis (MS) unresponsive to standard therapies, 1 based on reports of HSCT in experimental autoimmune encephalomyelitis and on the simple rationale that a renewed state of immune tolerance might be attained if the aberrant immune system was completely eradicated and replaced by a pristine, expectantly nonautoreactive, system generated from an autologous hemopoietic stem cell graft purged of autoimmune cells.
Nine years later, we reported an 80% probability of disease progression-free survival (PFS) at 5 years posttransplant in 35 patients having a median follow-up of 35 (range 3-67) months. Moreover, a major suppressive effect on disease activity was noted in brain MRI, while the procedure was associated with 3% mortality. 2 The purpose of this report, 15 years after the initiation of this still disputable therapy, is to communicate long-term results, the patients' median follow-up time being 11 (2-15) years.
METHODS Study design, patients, immunosuppressive regimen (conditioning), methods of transplantation, and neurologic assessment were previously described. 1 After approval by the institutional review board, 35 transplants were performed from June 1995 until May 2001 in patients who had progressed clinically by one EDSS step in the year preceding HSCT, with or without gadolinium-enhancing or new or enlarging lesions on MRI. The baseline clinical characteristics of these patients are summarized in the table. Median EDSS score was 6 (4.5-8) and 40% of cases had active disease on MRI.
Cyclophosphamide 4 g/m 2 and G-CSF 5-10 g/k.b.wt.
were administered before HSCT to mobilize and harvest hemopoietic stem cells to be used as a graft in order to rescue the patient after conditioning. To eliminate lymphocytes surviving the conditioning and also those in the graft, rabbit antithymocyte globulin (ATG 5-10 mg/kg.b.wt.) was infused in the peritransplant period while in 10 cases the grafts were also purged ex vivo by the CD34ϩ cell selection method. Three consecutive conditioning regimens were used: BEAM (BCNU 300 mg/m 2 ;
etoposide 800 mg/m 2 ; cytarabine 800 mg/m 2 ; melphalan 140 mg/m 2 ) in 15 patients, BEAM plus ex vivo CD34 cell selection in 10, and busulfan 16 mg/k.b.wt. in another 10. For neurologic assessments, the same 2 neurologists examined the patients every 3 months for the first 18 months and every 6 months until the third year, thereafter trying to keep the 6-months' contact whenever possible. Patients with stable or improved EDSS scores were considered responders. Progression was defined as an increase by 0.5 or 1 EDSS step if the previous scores were above 5 or below 5.5, assessed on 2 occasions 6 months apart. Deaths from any cause were calculated as failures. The Kaplan-Meier method was used to calculate the probability of PFS, defined as progression of the EDSS score above the corresponding baseline, before HSCT, score. Survival curves were compared by using the log-rank test. For the final evaluation, assessments were telephone-based in 15 cases, as previously described. 3 The impact of HSCT on brain gadolinium-enhancing lesions was analyzed using multilevel modeling for discrete longitudinal data (MLwiN, version 2). This is a powerful statistical analysis tool for repeated measures data, which can be used when the assumptions of the conventional analysis of variance for repeated measures are violated. Since our response variable consists of count data, we fit a multilevel Poisson model.
RESULTS
There were no casualties in the BEAMϩ ATG group; one patient died in each of the other groups, from aspergillosis 2 months after HSCT, and from pulmonary hemorrhage owing to the development of fVIII inhibitor (probably transplant-related) 2 1 ⁄2 years after HSCT. On final analysis, 3 more patients were reported dead: 1 from prostate cancer at 12 years, and 2 from MS-related complications at 10 and 14 years after HSCT.
Sixteen patients were improved after HSCT by 0.5-5.5 (median 1) EDSS points. Improvements lasted for a median of 2 years. Two patients have remained improved for 7 and 8 years; 7 eventually progressed beyond the baseline point; and in 7 patients scores have not exceeded baseline despite evidence of clinical activity. A life-saving response was seen in a patient with "malignant" MS. 4 PFS was 25% at 15 years and did not differ according to disease type, gender, conditioning, or EDSS score at transplantation. Median PFS was 5.4 years (95% CI 3-7.7 years) in secondary and relapsing MS, and 1.5 years (95% CI 0.95-1.95 years) in primary progressive disease ( p ϭ 0.338). Age below 35 and a short interval from diagnosis to HSCT seemed to yield better results. In patients with active MRI lesions, PFS was 44% at 15 years (median 11 years; 95% CI 0 -22), in contrast to 10% in patients without active lesions (median 2.3 years; 95% CI 0 -6) (p ϭ 0.01) (figure 1). A significant reduction in the number and volume of gadolinium-enhancing lesions was detected on MRI, which started after mobilization, became maximal after transplantation, and was thereafter sustained in time (figure 2). 
Secondary progressive MS ؎ relapses 19

Relapsing-progressing MS 3
Aggressive relapsing-progressive ("malignant") 1
Relapsing-remitting MS 1
Primary progressive MS 11
Previous therapies (combinations of) Steroids 35
Azathioprine 14
Interferon-␤ 13
Mitoxantrone 7 Abbreviations: EDSS ϭ Expanded Disability Status Scale; MS ϭ multiple sclerosis; SNRS ϭ Scripps Neurologic Rating Scale. a Two patients refused clinical assessments after the third posttransplant month and were not included in the Kaplan-Meier analysis of progression-free survival. b The case of the patient who died early, at day ϩ57 posttransplant, is not shown. All deceased cases were included in the calculation of progression-free survival.
Intravenous immunoglobulins 4
DISCUSSION
Despite the methodologic weakness of the study, the feeling is that HSCT, being a powerful anti-inflammatory and immunosuppressive treatment, may benefit patients with rapidly progressive MS. The most impressive results are observed on MRI and in the very aggressive MS cases 3,5-7 with prominence of inflammatory disease in the CNS. The debulking of autoreactive clones, complete suppression of inflammation, and, possibly, the qualitative immune changes induced by HSCT 8 may all play a beneficial role in slowing down disease progression. Immunologic changes do occur after HSCT: memory T cells decrease, thymic naïve CD4ϩ cells expand, creating a new and diverse TCR repertoire, and thymic CD4ϩ25ϩFoxP3 regulatory cells are generated. Whether these changes, however, are able to induce a permanent state of immune tolerance remains to be shown.
There is a paucity of long-term studies in MS, particularly focusing on patients with the baseline characteristics of our group, i.e., advanced and refractory disease with increasing disability. Daumer et al., 9 in an effort to assess the risk-benefit ratio of HSCT in MS, investigated the natural history of moderately severe MS in 258 untreated patients, concluding that the probability to reach an EDSS score of 10, i.e., death from MS, after 15 years was 22% (95% CI 4%-32%). In our study, patients had more advanced disease (baseline scores 4.5-8.0 vs 3.0 -5.5), and the combined procedure-and disease-related mortality at 15 years was 17%, comparing favorably with the mortality rates observed by Daumer et al. 9 The critical question whether HSCT is superior to conventional treatments cannot be answered on the basis of our uncontrolled data. Given the rapidity of progression before transplantation, the final status of our patients may be considered satisfactory, although disease progression, with or without an initial improvement, occurred in a significant proportion of patients. The European Group for Blood and Marrow Transplantation reported similar results in 178 patients from 45 centers, stressing the importance of patient selection (young, not too disabled, recently diagnosed) and the avoidance of overly toxic conditioning regimens, in order to minimize mortality, which in Europe is 2%-3%. 10 Because the mortality issue has remained of concern in the neurologic society and impeded adequate patient accrual in comparative studies, the superiority of HSCT over standard therapies has not yet been demonstrated in randomized trials, although more than 700 patients have been treated in phase I/II studies worldwide and good results have been claimed. Nevertheless, HSCT could be regarded as a salvage treatment of choice in "malignant" MS, in which comparative trials cannot be done and in which HSCT may yield dramatic results.
